Rosacea
main-banner
Rosacea
TRS-016 Enrolling

Clinical Trial for Papulopustular Rosacea (PPR) – 22 Weeks


Treatment: Topical Age: 18 Years

Adults aged 18-59 years (inclusive) with an at least 6-month history of papulopustular rosacea (PPR) are needed for a clinical trial. Eligible participants must have moderate to severe PPR and have 20 to 70 inflammatory lesions (papules and/or pustules) and no more than 2 nodules on the face. In addition, moderate or severe persistent erythema associated with PPR is also required for the study.

Participants will receive investigational topical treatment (active study drug) or placebo.  Study treatment and study-related assessments will be provided at no cost.  Reimbursement for study-related expenses may be provided.

Study participation will last approximately 22 weeks and involve about 6 visits to the study centre.


The following information is from ClinicalTrials.gov

Last Update Posted: February 22, 2023

Study Description

  • Condition or Disease:

    Rosacea

  • Ages Eligible for Study:

    18 to 59


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.


Participating Locations


Participating Experts

Dr. Kim Alexander Papp

Dermatologist

Dr. Melinda Gooderham

Dermatologist

Dr. Sheetal Sapra

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Rosacea

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials